Substance use

Vaping and schizophrenia: harm reduction or new problem?

April 16, 2026 9 min read

Vaping — the use of electronic cigarettes — is one of the most contested public-health topics of the past decade. In the UK, public health authorities have endorsed vaping as a quit-smoking aid. In the US, the FDA and CDC have taken a more cautious tone. For people with schizophrenia, who smoke at much higher rates and bear a disproportionate share of smoking-related premature death, the question matters more than for most populations.

In one sentence

Vaping is almost certainly less harmful than smoking combustible cigarettes for most measured outcomes — but it is not harmless, and dual use offers very little benefit.

What vaping is, briefly

An e-cigarette heats a liquid containing nicotine, propylene glycol, vegetable glycerine, and flavourings to produce an inhalable vapour. There is no combustion, which means no tar and dramatically less carbon monoxide and benzene than a cigarette. The nicotine content varies enormously, from low-strength refillable systems to high-strength disposable pods that can deliver more nicotine per puff than a cigarette.

What we know about relative harm

The most influential review remains the 2018 evidence update by Public Health England, which concluded that e-cigarettes are "around 95 percent less harmful than smoking" — a figure heavily cited and heavily criticised. Subsequent reviews from the World Health Organization have been more reserved, noting that long-term safety data is limited and that vaping is clearly not risk-free. Both perspectives can be true. The current consensus is roughly:

The Cochrane evidence on cessation

The 2024 update of the Cochrane review of e-cigarettes for smoking cessation by Hartmann-Boyce and colleagues found "high-certainty evidence" that nicotine e-cigarettes increase quit rates compared with NRT alone, and "moderate-certainty evidence" that they outperform behavioural support alone. This is the strongest endorsement vaping has received from a major systematic review body. It does not mean vaping is risk-free — it means that for someone who has not been able to quit with NRT or counselling, vaping is a reasonable next step.

What about schizophrenia specifically?

Direct trial evidence in schizophrenia is limited. A small Italian study by Caponnetto and colleagues (European Addiction Research, 2013) followed 14 people with schizophrenia who were given e-cigarettes; about half reduced cigarette consumption by more than 50 percent at one year, and there were no negative effects on psychiatric symptoms. Larger pragmatic trials are ongoing. The more important data point is mechanistic: nicotine itself does not appear to worsen psychotic symptoms, and removing combustion products is biologically likely to benefit cardiovascular and respiratory outcomes that drive premature mortality in this population.

The CYP1A2 question

Important medication interaction

The CYP1A2-inducing effect that lowers clozapine and olanzapine levels is caused by polycyclic aromatic hydrocarbons in tobacco smoke — not by nicotine. Switching from cigarettes to vaping removes the smoke and therefore raises levels of these medications, sometimes substantially. Tell your prescriber before switching so they can plan a dose review and, for clozapine, a level check.

The risks worth taking seriously

EVALI

The 2019 outbreak of e-cigarette or vaping product use-associated lung injury (EVALI) was traced almost entirely to vitamin E acetate in unregulated THC vape cartridges, not to commercial nicotine vapes. Sticking to regulated nicotine products substantially reduces this risk.

Nicotine dependence

High-strength pod systems (such as those delivering 5 percent nicotine salts) can produce dependence quickly, sometimes more rapidly than cigarettes. Some users find themselves vaping more total nicotine per day than they previously smoked.

Long-term respiratory effects

Vaping is associated with increased rates of cough, wheeze, and asthma exacerbation. The long-term cancer risk appears much lower than smoking but is not zero, and decades-long data simply do not yet exist.

Cardiovascular effects

Acute exposure raises heart rate and blood pressure. Long-term cardiovascular harm appears smaller than smoking but again is not fully characterised.

Practical guidance

If you smoke and have not been able to quit with NRT or varenicline, switching completely to a regulated nicotine vape is a reasonable harm-reduction step. The keyword is completely. Things that improve the odds:

What if you don't smoke?

Don't start. There is no scenario in which someone who has never smoked benefits from picking up vaping. The brief cognitive effects of nicotine in schizophrenia (see our deep article) do not justify initiating a new dependence with its own physical and financial costs.

The honest bottom line

Vaping is best understood as a harm-reduction tool for people who already smoke and have not been able to quit with first-line methods. It is not a "safe" alternative to be promoted in absolute terms. For someone with schizophrenia who has been smoking heavily for years and has cardiovascular or respiratory disease accumulating, switching completely is likely to be a meaningful step forward. The decision belongs to you and your clinician.


This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.

Frequently asked questions

Is vaping really 95 percent safer than smoking?
The 95 percent figure from Public Health England is widely cited but uncertain. The more defensible statement is that vaping is substantially less harmful than smoking on most measured short-term outcomes, with long-term safety still being established.
Can vaping cause psychotic symptoms?
Nicotine vapes do not appear to worsen psychotic symptoms. Vaping THC products is a different question — high-potency cannabis use is associated with increased psychosis risk, particularly during early illness.
Will my insurance cover vapes?
Generally no. NRT and varenicline are typically covered; vapes are not classified as medical products by the FDA. UK NHS stop-smoking services in some regions provide e-cigarettes free of charge.
Is dual use (smoking and vaping) safer than smoking alone?
Only marginally, and most studies find dual users have similar or only slightly lower exposure to combustion toxins than exclusive smokers. Switching completely is what matters.

Try Frida — your calm companion

Frida helps people living with schizophrenia track moods, manage medication, and build stability. 7-day free trial.

Get the app →